Related Experiment Videos
Renal bone disorders in children: therapy with vitamin D3 or 1,25-dihydroxycholecalciferol
Insights
Vitamin D therapy improved secondary hyperparathyroidism in children with chronic renal failure and on dialysis. However, active vitamin D was more effective but carried risks like hypercalcemia.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Secondary hyperparathyroidism is a common complication in children with chronic renal failure (CRF) and those on regular dialysis therapy (RDT).
- Vitamin D deficiency and impaired vitamin D metabolism contribute to renal bone disease in these pediatric populations.
- Effective management of renal osteodystrophy is crucial for improving long-term outcomes in children with kidney disease.
Purpose of the Study:
- To evaluate the efficacy of vitamin D3 and 1,25(OH)2D3 in treating secondary hyperparathyroidism and renal bone disease in children with CRF and RDT.
- To assess the impact of these vitamin D analogs on calcium, parathyroid hormone (PTH) levels, and bone histology.
- To determine the safety profile and potential adverse effects of vitamin D therapy in pediatric kidney disease patients.
Main Methods:
- A cohort of children with CRF and RDT received varying doses of vitamin D3 (10,000–50,000 IU daily).
- A subset of RDT patients were subsequently treated with 1,25(OH)2D3.
- Serum calcium, PTH levels, intestinal calcium absorption, and bone histology (fibro-osteoclasia, osteoidosis) were monitored.
Main Results:
- Vitamin D3 treatment increased serum calcium and reduced PTH levels, improving secondary hyperparathyroidism in CRF patients, but not completely preventing it.
- In RDT patients, vitamin D3 improved secondary hyperparathyroidism in 50% of cases, with some relapses occurring.
- 1,25(OH)2D3 normalized calcium, suppressed PTH, improved calcium absorption, and healed fibro-osteoclasia, but commonly caused hypercalcemia and potential calcification.
Conclusions:
- Vitamin D3 offers partial improvement for secondary hyperparathyroidism in pediatric kidney disease.
- Active vitamin D (1,25(OH)2D3) is more effective for severe renal bone disease but requires careful monitoring due to hypercalcemia risk.
- Neither vitamin D3 nor 1,25(OH)2D3 guarantees complete resolution of osteodystrophy or growth arrest in uremic children.
Abstract:
Twelve children with chronic renal failure (CRF) and sixteen children receiving regular dialysis therapy (RDT) were treated with between 10,000 and 50,000 IU of vitamin D daily. This was associated with an increase in serum calcium levels and reduction in PTH levels. In the children with CRF, secondary hyperparathyroidism was improved with treatment but its development was not completely prevented nor was healing complete. In the patients receiving RDT, treatment with vitamin D improved the changes associated with secondary hyperparathyroidism in 50% of cases but these features sometimes reappeared despite continuing treatment. Hypercalcaemia or metastatic calcification was not seen. Subsequently, 1,25(OH)2D3 was administered to 14 children receiving RDT. This was associated with the return of serum calcium levels to normal, inhibition of PTH synthesis and an improvement in intestinal calcium absorption. Fibro-osteoclasia was cured and there was improvement in actual bone resorption. There was also improvement in osteoidosis in those children who showed disturbances of mineralisation. Calcification in the limbus area of the eyes may occur and hypercalcaemia was seen commonly. Treatment with 1,25(OH)2D3 should only be offered to children with severe renal bone disease. Neither vitamin D3 nor 1,25(OH)2D3 can guarantee complete recovery of osteodystrophy and of growth arrest in uraemic children.